Literature DB >> 28493597

R-warfarin anticoagulant effect.

Roberto Padrini1, Luigi Quintieri2.   

Abstract

Entities:  

Keywords:  R-warfarin; modelling and simulation; pharmacodynamics

Mesh：

Substances：

Year:  2017        PMID： 28493597      PMCID： PMC5595941          DOI： 10.1111/bcp.13300

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

Authors:  A-K Hamberg; M-L Dahl; M Barban; M G Scordo; M Wadelius; V Pengo; R Padrini; E N Jonsson
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

Review 2.  Human P450 metabolism of warfarin.

Authors:  L S Kaminsky; Z Y Zhang
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

3.  Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.

Authors:  Benjamin C Lewis; Pramod C Nair; Subash S Heran; Andrew A Somogyi; Jeffrey J Bowden; Matthew P Doogue; John O Miners
Journal:  Pharmacogenet Genomics       Date:  2016-01       Impact factor: 2.089

4.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

5.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.

Authors:  A Breckenridge; M Orme; H Wesseling; R J Lewis; R Gibbons
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

6.  The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.

Authors:  John Maddison; Andrew A Somogyi; Berit P Jensen; Heather M James; Melanie Gentgall; Paul E Rolan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.

Authors:  Ling Xue; Nick Holford; Xiao-Liang Ding; Zhen-Ya Shen; Chen-Rong Huang; Hua Zhang; Jing-Jing Zhang; Zhe-Ning Guo; Cheng Xie; Ling Zhou; Zhi-Yao Chen; Lin-Sheng Liu; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2016-11-25       Impact factor: 4.335

8.  Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.

Authors:  E Chan; A McLachlan; R O'Reilly; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

9.  Human prothrombin metabolism in normal man and in hypocoagulable subjects.

Authors:  S S Shapiro; J Martinez
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971
View more
  2 in total

1.  Response to R-warfarin anticoagulant effect.

Authors:  Ling Xue; Nick Holford; Li-Yan Miao
Journal:  Br J Clin Pharmacol       Date:  2017-07-23       Impact factor: 4.335

2.  Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.

Authors:  Carlo Federico Zambon; Vittorio Pengo; Stefania Moz; Dania Bozzato; Paola Fogar; Andrea Padoan; Mario Plebani; Francesca Groppa; Giovanni De Rosa; Roberto Padrini
Journal:  Eur J Clin Pharmacol       Date:  2018-02-02       Impact factor: 2.953
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.